Publication Name	World Journal of Gastroenterology
Manuscript ID	5650
Country	Brazil

Received	2013-09-20 10:04
Peer-Review Started	2013-09-21 19:37
To Make the First Decision	2013-10-14 21:27
Return for Revision	2013-10-20 21:16
Revised	2013-11-11 08:25
Second Decision	2014-01-06 17:59
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-01-06 19:05
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-02-28 15:10
Publish the Manuscript Online	2014-03-18 14:14

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Chronic hepatitis C genotype 1 virus: Who should wait for treatment?
Manuscript Source	Invited Manuscript
All Author List	Cristiane Valle Tovo, Angelo Alves de Mattos and Paulo Roberto Lerias de Almeida
Funding Agency and Grant Number
Corresponding Author	Cristiane Valle Tovo, MD, PhD, Department of Gastroenterology, Universidade Federal de Ciências da Saúde de Porto Alegre, Rua Cel Aurélio Bitencourt 115 apto 201, Porto Alegre 90430-080, Brazil. cris.tovo@terra.com.br
Key Words	Hepatitis C virus; Chronic hepatitis C; Treatment of hepatitis C; Cirrhosis; Protease inhibitors
Core Tip	Identification of risk factors for progression of chronic hepatitis C has allowed physicians to recommend treatment deferral (triple therapy) to wait for anticipated new drugs with better efficacy and safety profiles for patients with mild to moderate disease. Patients with cirrhosis and prior null responders rarely obtain sustained virological response with triple therapy and the decision to wait for new treatments must be considered. For each patient population, definitive clinical management guidelines are needed to maximize the benefit of waiting for new drugs and minimize risk of side effects and non-response to the current triple therapy.
Publish Date	2014-03-18 14:14
Citation	Tovo CV, Alves de Mattos A, Lerias de Almeida PR. Chronic hepatitis C genotpype 1 virus: Who should wait for treatment? World J Gastroenterol 2014; 20(11): 2867-2875
URL	http://www.wjgnet.com/1007-9327/full/v20/i11/2867.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i11.2867

Full Article (PDF)	WJG-20-2867.pdf
Full Article (Word)	WJG-20-2867.doc
Manuscript File	5650-Review.doc
Answering Reviewers	5650-Answering reviewers.pdf
Copyright License Agreement	5650-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	5650-Language certificate.pdf
Peer-review Report	5650-Peer reviewer(s).pdf
Scientific Editor Work List	5650-Scientific editor work list.doc